Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again

Jules Higué, Gaetan Basile, Titouan Cazaubiel, Anne Banos, Guillaume Beziat, Martin Gauthier, Miguel Carreiro, Noemie Gadaud, Benjamin Hebraud, Miguel Granell, Pierre Bories, Christian Récher, Jill Corre, Cyrille Hulin, Aurore Perrot, Leopoldine Lapierre, Pierre Luc Mouchel

Blood (2024) 144 (Supplement 1): 7030.

https://doi.org/10.1182/blood-2024-206954

Published: 2024

Journal Articles

French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma

Benjamin Hebraud, Miguel Granell, Leopoldine Lapierre, Pierre Luc Mouchel, Guillaume Beziat, Nina Sicard, Maeva Bonneau, Jules Higue, Florence Sougy, Sophie Perriat, Charlotte Morel, Pierre Bories, Jill Corre, Herve Avet Loiseau, Christian Recher, Aurore Perrot

Blood (2023) 142 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2023-179727

Published: 2023

Journal Articles

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Jules Higué, Pierre-Yves Dumas, Laetitia Largeaud, Audrey Bidet, Émilie Klein, Olivier Mansier, Lucie Rigolot, Eric Delabesse, Anne Banos, Suzanne Tavitian, Thibaut Leguay, Sarah Guenounou, Edouard Forcade, Sarah Bertoli, Arnaud Pigneux, Christian Recher

Blood (2023) 142 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2023-180773

Published: 2023